Proposed Remedy For 340B Acquired DrugPayment Policyfor 2018-2022

On July 7, 2023, in light of the Supreme Court?s decision in American Hospital Association v. Becerra (142 S. Ct. 1896 (2022)) and the district court?s remand to the agency, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule outlining the proposed remedy for the 340B-acquired drug payment policy for Calendar Years 2018-2022.

CMSis publishing this proposed rule to remedy the payment rates the Court held were invalid Aspects of this proposed policy will affect nearly all hospitals paid under the OPPS

This proposed rule will have a 60-day comment period, which will end onSeptember 5, 2023 This fact sheet discusses the provisions of theproposedrule (CMS- 1793-P), which can be downloaded at https://www federalregister gov/public-inspection/2023-14623/medicare-program-hospital -outpatient-prospective-payment-system-remedy-for-the-340b-acquired-drug CMSanticipates issuing the final rule before the Calendar Year (CY) 2024 Outpatient Prospective Payment System/Ambulatory Surgery Center (OPPS/ASC) final rule is published in Fall 2023.

Background

Section 340B of the Public Health Service Act (340B) allows participating hospitals and other providers to purchase certain covered outpatient drugs or biologicals (hereinafter referred to collectively as ?drugs?) from manufacturers at discounted prices. Prior to 2018, the Medicare payment rate for Part B covered outpatient drugs provided in outpatient hospitals was generally the statutory default of average sales price (ASP) plus 6% In the CY2018 OPPS/ASC final rule that was finalized in 2017, CMSadjusted the payment rate for 340B drugs to ASP minus 22 5%to reflect more accurately the actual costs incurred by 340B hospitals when acquiring 340B drugs.

This rate applied from CY2018 through approximately the third quarter of CY2022. To comply with statutory budget neutrality requirements under the OPPS, CMSmade a corresponding increase to payments to all hospitals (340B hospitals and non-340B hospitals) for non-drug items and services, which was in effect from CY2018 through CY2022

On June 15, 2022, the Supreme Court unanimously ruled that the differential payment rates for 340B-acquired drugs were unlawful because, prior to implementing the rates, HHSfailed to conduct a survey of hospitals?acquisition costs under the relevant statute.

On September 28, 2022, the District Court for the District of Columbia vacated the differential payment rates for 340B-acquired drugs going forward As a result, all CY2022 claims for 340B-acquired drugs paid on or after September 28, 2022, were paid at the default rate (generally ASP plus 6%).

In the CY2023 OPPS/ASCfinal rule, CMSfinalized a general payment rate of ASPplus 6%for drugs acquired through the 340B Program, consistent with the agency?s policy for drugs not acquired through the 340B program As required by statute, CMSimplemented a 3.09% reduction to the payment rates for non-drug items and services to achieve budget neutrality for the 340B drug payment rate change for CY2023.

This budget neutrality change ensured the CY2023 OPPSconversion factor was equivalent to the conversion factor that would have been in place had the 340B drug payment policy never been implemented.

In the CY2023 OPPS/ASCfinal rule, CMSannounced that it would address the remedy for 340B drug payments from CY2018-2022 in future rulemaking prior to the release of the CY2024 OPPS/ASCproposed rule.

Proposed Rem edy for t he 340B-Acquired Drug Paym ent Policy for Calendar Years 2018-2022

Lump Sum Paymentsto Affected Providersfor 340B-Acquired Drugs

In the proposed rule, CMSis proposing to make an additional payment to affected providers for 340B-acquired drugs as a one-time lump sum payment. CMSestimates that for CY2018 through the approximate third quarter of 2022, certain OPPS340B providers received $10.5 billion less in 340B drug payments than they would have without the 340B policy.

However, many CY2022 340B drug claims have been processed, or reprocessed through standard claims processing, at the higher default payment rate since the 340B payment policy was vacated on September 27, 2022

As a result, affected 340B providers have already received from Medicare and beneficiaries $1 5 billion of the $10 5 billion that would otherwise have had to be remedied through these reprocessed claims For the remaining $9 billion owed to affected 340B providers for claims covering CYs 2018 through 2022, CMSis proposing to make a one-time lump-sum payment to each 340B-covered entity hospital that was paid less due to the now-invalidated policy. The proposed rule contains the calculations of the amounts owed to each of the approximately 1,600 affected 340B covered entity hospitals

Beneficiary Copayments

Beneficiary copayments make up approximately 20%of the payments affected 340B covered entity hospitals did not receive due to the 340B payment policy Because CMSplans to structure the remedy as a lump-sum remedy payment, providers would not be able to bill beneficiaries for that cost sharing. To account for that fact and to ensure that affected 340B providers are put in as close to the same position as if the 340B payment policy had never existed, Medicare proposes to account for beneficiary cost sharing within the one-time lump sum payment to affected hospitals. Under this proposal, affected 340B covered entity hospitals may not bill beneficiaries for coinsurance on remedy payments.

Prospective Offset for Higher Payments for Non-Drug Items and Services from CY 2018-2022

As part of this proposed remedy, CMSproposes to maintain budget neutrality as required by statute As described above, CMSfinalized the 340B policy for CY2018 in 2017 in a budget neutral manner that included increasing payments for non-drug items and services; this payment increase was in effect from CY2018 through CY2022 CMSestimates that hospitals were paid $7.8 billion more for non-drug items and services during this time period than they would have been paid in the absence of the 340B payment policy Because CMSis now making additional payments to affected 340B covered entity hospitals to pay them what they would have been paid had the 340B policy never been implemented, CMSproposes to make a corresponding offset to maintain budget neutrality as if the 340B payment policy had never been in effect. To carry out this required $7.8 billion budget neutrality adjustment, CMSis proposing to reduce future non-drug item and service payments by adjusting the OPPS conversion factor by minus 0.5%starting in CY2025. CMSproposes to continue making this adjustment until the full $7 8 billion is offset, which CMSestimates to be 16 years